Oregon Public Employees Retirement Fund lifted its position in Zoetis Inc. (NYSE:ZTS) by 51.0% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 136,286 shares of the company’s stock after purchasing an additional 46,045 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Zoetis were worth $22,555,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently modified their holdings of the company. BlackRock Inc. lifted its stake in shares of Zoetis by 3.3% in the fourth quarter. BlackRock Inc. now owns 40,720,915 shares of the company’s stock worth $6,739,311,000 after buying an additional 1,291,599 shares during the last quarter. Alliancebernstein L.P. lifted its stake in shares of Zoetis by 9.1% in the fourth quarter. Alliancebernstein L.P. now owns 16,645,263 shares of the company’s stock worth $2,754,791,000 after buying an additional 1,386,823 shares during the last quarter. FMR LLC lifted its stake in shares of Zoetis by 27.4% in the fourth quarter. FMR LLC now owns 14,036,704 shares of the company’s stock worth $2,323,075,000 after buying an additional 3,017,046 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Zoetis by 0.3% in the third quarter. Massachusetts Financial Services Co. MA now owns 6,289,978 shares of the company’s stock worth $1,040,174,000 after buying an additional 18,576 shares during the last quarter. Finally, UBS Asset Management Americas Inc. lifted its stake in shares of Zoetis by 0.7% in the third quarter. UBS Asset Management Americas Inc. now owns 4,849,392 shares of the company’s stock worth $801,944,000 after buying an additional 33,871 shares during the last quarter. Institutional investors and hedge funds own 92.50% of the company’s stock.
A number of research analysts have recently commented on ZTS shares. Barclays upped their price objective on shares of Zoetis from $175.00 to $189.00 and gave the company an “overweight” rating in a research report on Friday, November 6th. Truist raised their price objective on Zoetis from $160.00 to $170.00 in a research report on Thursday, November 12th. Credit Suisse Group lifted their price objective on Zoetis from $197.00 to $203.00 in a report on Wednesday, February 17th. Finally, Morgan Stanley upped their target price on Zoetis from $167.00 to $174.00 and gave the company an “equal weight” rating in a research note on Friday, November 13th. Seven equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Zoetis has a consensus rating of “Buy” and a consensus price target of $167.25.
Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, February 16th. The company reported $0.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.86 by $0.05. Zoetis had a net margin of 25.50% and a return on equity of 63.89%. During the same period last year, the business posted $0.92 EPS. Analysts anticipate that Zoetis Inc. will post 3.63 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 1st. Stockholders of record on Wednesday, April 21st will be issued a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 0.63%. The ex-dividend date is Tuesday, April 20th. Zoetis’s payout ratio is 27.47%.
In related news, EVP Heidi C. Chen sold 1,180 shares of the company’s stock in a transaction dated Tuesday, December 1st. The shares were sold at an average price of $161.64, for a total transaction of $190,735.20. Following the transaction, the executive vice president now owns 17,515 shares in the company, valued at approximately $2,831,124.60. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Robert Edward Kelly sold 2,054 shares of the company’s stock in a transaction dated Thursday, February 11th. The stock was sold at an average price of $161.15, for a total transaction of $331,002.10. Following the transaction, the executive vice president now owns 10,029 shares in the company, valued at approximately $1,616,173.35. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,734 shares of company stock worth $2,217,592. 0.17% of the stock is owned by insiders.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Read More: Calculate Your Return on Investment (ROI)
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.